RegeneRx Biopharmaceuticals, Inc. (RGRX)

OTCMKTS · Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
Feb 27, 2026, 4:00 PM EST
-78.57%
Market Cap 453.00
Revenue (ttm) 76.76K
Net Income (ttm) -1.69M
Shares Out 1.51M
EPS (ttm) -1.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 252
Average Volume 1,900
Open 0.1610
Previous Close 0.0003
Day's Range 0.0003 - 0.1610
52-Week Range 0.0002 - 0.1630
Beta 179.89
RSI 46.73
Earnings Date n/a

About RGRX

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tβ4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee’s Pharmaceutical Group for the development and marketing of Tβ4-related products; and HLB Therapeutics for the development and marketing of RGN-259, and RGN-137 f... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1982
Employees 3
Stock Exchange OTCMKTS
Ticker Symbol RGRX
Full Company Profile

Financial Performance

In 2022, RGRX's revenue was $76,761, a change of 0.00% compared to the previous year's $76,761. Losses were -$1.73 million, 8.12% more than in 2021.

Financial Statements

News

There is no news available yet.